Market Closed -
Japan Exchange
02:00:00 2024-06-10 am EDT
|
5-day change
|
1st Jan Change
|
211
JPY
|
+3.94%
|
|
+0.48%
|
+12.23%
|
Fiscal Period: February |
2025
|
2026
|
2027
|
---|
Capitalization
1 |
8,504
|
-
|
-
|
Enterprise Value (EV)
1 |
8,504
|
8,504
|
8,504
|
P/E ratio
|
-6.34
x
|
-6.34
x
|
-5.34
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
18.1
x
|
EV / Revenue
|
-
|
-
|
18.1
x
|
EV / EBITDA
|
-6.72
x
|
-6.59
x
|
-5.59
x
|
EV / FCF
|
-9.45
x
|
-6.54
x
|
-5.44
x
|
FCF Yield
|
-10.6%
|
-15.3%
|
-18.4%
|
Price to Book
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,304
|
-
|
-
|
Reference price
2 |
203.0
|
203.0
|
203.0
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2025
|
2026
|
2027
|
---|
Net sales
1 |
-
|
-
|
468.8
|
EBITDA
1 |
-1,265
|
-1,290
|
-1,521
|
EBIT
1 |
-1,275
|
-1,300
|
-1,531
|
Operating Margin
|
-
|
-
|
-326.58%
|
Earnings before Tax (EBT)
1 |
-1,275
|
-1,300
|
-1,531
|
Net income
1 |
-1,275
|
-1,300
|
-1,531
|
Net margin
|
-
|
-
|
-326.58%
|
EPS
2 |
-32.00
|
-32.00
|
-38.00
|
Free Cash Flow
1 |
-900
|
-1,300
|
-1,562
|
FCF margin
|
-
|
-
|
-333.3%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2025
|
2026
|
2027
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
1 |
-900
|
-1,300
|
-1,563
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
Capex
1 |
10
|
10
|
10
|
Capex / Sales
|
-
|
-
|
2.13%
|
Announcement Date
|
-
|
-
|
-
|
Average target price
760
JPY Spread / Average Target +274.38% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.23% | 52.25M | | +51.85% | 57.87B | | +41.59% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|